Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
TRIXEO AEROSPHERE is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.1
Limitation of use: Not for acute use.
This medicinal product is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy1
For illustration purposes only. Not to scale.
The TRIXEO inhaler ingredients are glycopyrronium, formoterol and budesonide.
Induces bronchodilation through inhibition of the M3 receptor at the smooth muscle1
Rapidly and effectively relaxes the central and peripheral airways1
Anti-inflammatory action throughout the large and small airways1
TRIXEO is administered through the TRIXEO AEROSPHERE inhaler, equipped with next-generation device delivery technology.1, 6-8
If a TRIXEO dose is missed, it should be taken as soon as possible, and the next TRIXEO dose should be taken at the usual time.
A double dose should not be taken to make up for a forgotten dose.
TRIXEO patients should not take more than the recommended and maximum dose of two puffs twice a day on the same day.
Annual rates 1.08 vs 1.42; RR 0.76, 95% CI 0.69–0.83, p<0.001; ARR 0.34 exacerbations per patient per year. NNT 310
Annual rates 1.08 vs 1.24;
RR 0.87, 95% CI 0.79–0.95,
p=0.003; ARR 0.16
exacerbations per patient
per year. NNT 610
ICS/LABA (BFF) AEROSPHERE pMDI is not licensed in the UK and is confirmed as non-inferior to the UK licensed ICS/LABA (BFF) DPI by KRONOS study
Access a range of resources to help support you and your patients, including expert-led webinars and patient user guides.
ARR, absolute rate reduction; BFF, budesonide/formoterol fumarate; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; GFF, glycopyrronium/formoterol fumarate; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; NNT, number needed to treat; pMDI, pressurised metered-dose inhaler; RR, rate ratio.
GB-70571 | Sept 2025
TRIXEO and AEROSPHERE are registered trademarks of the AstraZeneca group of companies.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
